We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Risk-Evaluation Guidance Unlikely To Help Generics

Law360 (June 12, 2018, 2:55 PM EDT) -- Last week, the U.S. Food and Drug Administration issued two draft guidances concerning risk evaluation mitigation strategies, or REMS, which are programs designed to track the use, and deter the potential misuse, of drug products that pose significant health risks. One guidance addressed the development of a single shared system for REMS.[1] The other addressed waivers from the SSS for REMS.[2] The FDA proffered these guidances as a means of enhancing cooperation and competition in response to complaints that brand drug manufacturers were using REMS requirements...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.